No Additional Benefit From Tiragolumab Plus Atezolizumab Over Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation By Ogkologos - August 24, 2026 94 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SKYSCRAPER-03 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR How repurposing a drug in a COVID-19 trial could benefit people... March 2, 2021 Neoadjuvant Docetaxel, Oxaliplatin, and S-1, as Part of Perioperative Chemotherapy, Prolongs... August 19, 2024 FDA Approves Enfortumab Vedotin-ejfv with Pembrolizumab for Locally Advanced or Metastatic... January 8, 2024 Berry Recipes August 14, 2020 Load more HOT NEWS Metformin May Affect Risk of Breast Cancer in Women with Type... Brentuximab Approved for High-Risk Hodgkin Lymphoma in Children and Adolescents Getting through the Holidays-With a Little Help From Oncolink Supplemental Breast Cancer Imaging Techniques Could Lead to Earlier Detection of...
